Summary Of: Zidovudine

Encyclodia Page On: Zidovudine

These Are Links To Other Documents

| | IUPAC | CAS number | ATC code | J05 | PubChem | DrugBank | Formula | C | H | N | O | Mol. mass | SMILES | Bioavailability | Protein binding | Metabolism | Hepatic | Half life | Excretion | Renal | Pregnancy cat. | US | Legal status | Routes | INN | nucleoside analog reverse transcriptase inhibitor | antiretroviral drug | HIV | Combivir | Trizivir | analog | thymidine | Jerome Horwitz | Wayne State University School of Medicine | US | National Institutes of Health | grant | cancer | Samuel Broder | Hiroaki Mitsuya | Robert Yarchoan | National Cancer Institute | GlaxoSmithKline | in vitro | clinical trial | CD4 | placebo | randomized trial | Food and Drug Administration | March 20 | 1987 | anemia | antiretroviral drugs | highly active antiretroviral therapy | Aberdeen University | hydrogen bond | | | mother-to-child transmission | cesarean section | anemia | bone marrow suppression | erythropoietin | darbepoetin | mitochondria | ribavirin | hepatic | glucuronidation | indomethacin | acetylsalicylic acid | trimethoprim | mutation | reverse transcriptase | citation needed | reverse transcriptase inhibitor | protease inhibitor | non-nucleoside reverse transcriptase inhibitor | | | reverse transcriptase inhibitors | reverse transcriptase | enzyme | DNA | RNA | DNA | cell | provirus | lipophilic | cell membranes | diffusion | blood-brain barrier | DNA polymerase | cell division | mitochondria | myositis | Public Citizen | United States Court of Appeals for the Federal Circuit | Burroughs Wellcome | AIDS Healthcare Foundation | patent | public domain | GlaxoSmithKline | generic | New York Times | September 20 | 1986 | March 17 | 2008 | doi | doi | doi | doi | doi | doi | doi | doi | doi | The Best Democracy Money Can Buy | Greg Palast | v | d | Antivirals | HIV | HAART | J05 | Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) | Abacavir (ABC) | Emtricitabine (FTC) | KP-1461 | Lamivudine (3TC) | Tenofovir | Didanosine (ddI) | Apricitabine | Stampidine | Elvucitabine | Racivir | Amdoxovir | Stavudine (d4T) | Zalcitabine (ddC) | Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) | Efavirenz | Nevirapine | Etravirine | Rilpivirine | Loviride | Delavirdine | Protease Inhibitors (PI) | Atazanavir | Brecanavir | Fosamprenavir | Lopinavir | Darunavir | Nelfinavir | Ritonavir | Saquinavir | Tipranavir | Amprenavir | Indinavir | Entry/fusion inhibitors | Aplaviroc | Enfuvirtide | Maraviroc | Vicriviroc | PRO 140 | Ibalizumab | Integrase inhibitors | Raltegravir | Elvitegravir | Maturation inhibitors | Bevirimat | Vivecon | Combined formulations | Combivir | Atripla | Trizivir | Truvada | Kaletra | Epzicom | Abzyme | Calanolide A | Ceragenin | Cyanovirin-N | Diarylpyrimidines | Epigallocatechin gallate (EGCG) | Foscarnet | Globoidnan A | Griffithsin | Hydroxyurea | Miltefosine | Portmanteau inhibitors | Seliciclib | Synergistic enhancers | Tre recombinase | Zinc finger protein transcription factor | DHHS | first-line agent | clinical trials | FDA | Development | Categories | Nucleoside analog reverse transcriptase inhibitors | All articles with unsourced statements | Articles with unsourced statements since October 2008 |